Targeting HIF-1 for Cancer Therapy

Nat Rev Cancer. 2003 Oct;3(10):721-32. doi: 10.1038/nrc1187.

Abstract

Hypoxia-inducible factor 1 (HIF-1) activates the transcription of genes that are involved in crucial aspects of cancer biology, including angiogenesis, cell survival, glucose metabolism and invasion. Intratumoral hypoxia and genetic alterations can lead to HIF-1alpha overexpression, which has been associated with increased patient mortality in several cancer types. In preclinical studies, inhibition of HIF-1 activity has marked effects on tumour growth. Efforts are underway to identify inhibitors of HIF-1 and to test their efficacy as anticancer therapeutics.

Publication types

  • Review

MeSH terms

  • Animals
  • DNA-Binding Proteins / antagonists & inhibitors*
  • DNA-Binding Proteins / physiology
  • Disease Models, Animal
  • Humans
  • Hypoxia-Inducible Factor 1
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Mice
  • Neoplasms / drug therapy*
  • Neoplasms / genetics
  • Neoplasms / physiopathology*
  • Nuclear Proteins / antagonists & inhibitors*
  • Nuclear Proteins / physiology
  • Transcription Factors*

Substances

  • DNA-Binding Proteins
  • HIF1A protein, human
  • Hif1a protein, mouse
  • Hypoxia-Inducible Factor 1
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Nuclear Proteins
  • Transcription Factors